Yoona Choi and Jung-Hyun Won attended the 65th Annual Meeting & Exposition of the American Society of Hematology (ASH), which took place from December 9 to 12, 2023, in San Diego, USA. Annually, the ASH conference brings together healthcare professionals, researchers, clinicians, and academics from around the globe to explore advancements in hematology. This prestigious event not only focuses on the study, diagnosis, treatment, and prevention of blood disorders but also features a variety of social events and opportunities for collaboration and the sharing of insights among experts in the field. Official photos from ASH are available here.

At the 'Outcomes Research—Lymphoid Malignancies: Poster II' session, Yoona Choi, serving as the first author and representing the entire research team, presented a study titled 'Evaluating the Effectiveness and Safety of Prephase Steroid Treatment before Remission Induction Chemotherapy in Pediatric Acute Lymphoblastic Leukemia: A Common Data Model-Based Real-World Data Approach.' This study investigated steroid pretreatment in pediatric acute lymphoblastic leukemia (ALL) patients undergoing remission induction chemotherapy (RIC), with the aim of reducing complications such as tumor lysis syndrome (TLS). Analyzing data from Seoul National University Hospital and Catholic University Seoul St. Mary’s Hospital, the study compared patients who received steroid pretreatment at least seven days before RIC with those who did not. The findings indicated a significant reduction in TLS incidence in the pretreated group. While overall survival rates were higher in this group, the difference was not statistically significant. These results provide important real-world evidence for the effectiveness of steroid pretreatment in reducing TLS risk in pediatric ALL patients.

This study was part of a larger project, funded by a grant from the Ministry of Health and Welfare, aiming to develop a disease registry database for pediatric ALL using real-world data in the clinical data warehouse (CDW) of Seoul National University Hospital and Catholic University Seoul St. Mary’s Hospital, thereby generating real-world evidence for pediatric ALL. 

Yesol Hong won the Excellent Research Award at the 30th Annual Conference of the Korean Society for Clinical Pharmacology & Therapeutics (KSCPT), December 1-3, 2022, held at Bexco, Busan, South Korea. The title of YeSol's presentation was "One-year follow-up of patients with COVID-19: Analysis of new-onset disease after COVID-19 diagnosis using Real-World Data". She discussed the results of an analysis of the occurrence of disease in patients with COVID-19 over a year using two different real-world data sets. One of her analysis results was a nation-wide study, which was significant in that it included the largest number of study subjects among the studies analyzing the post-COVID-19-condition in Korea. Jung Hyun Won equally contributed to this study with Professor Howard Lee serving as the principal investigator.

Additionally, Siun Kim, Yoona Choi, David Seung U Lee also presented their research through poster exhibition at the conference. 

Full presentations can be watched at the following YouTube links: 

YeSol had the honor to deliver oral presentation and won the Excellent Research Award at 2022 fall conference hosted by the Korean Society of Medical Informatics(KOSMI). YeSol has presented her work entitled "Effectiveness and safety of sodium-glucose cotransporter-2 inhibitors(SGLT2i) added to mono, dual or triple treatment in patients with type 2 diabetes mellitus(T2DM)". She discussed the additive efficacy in glycemic control and the tolerability of SGLT2i in T2DM patients when combined with other antihyperglycemic agents, such as metformin, sulfonylureas, and dipeptidyl peptidase-4 inhibitors using real-world data. Yoona Choi, TaeKyu Chung, and Yoomin Jeon also contributed to this study as co-researchers, with Professor Howard Lee serving as the principle investigator.

The conference was a three-day event (from Nov 23rd, 2022 to Nov 25th, 2022) and was held at The International Convention Center, Jeonbuk National University, Jeonju, Jeonbuk, South Korea. This conference, the host(KOSMI) organized the event around the theme, "The Power and Value of Healthcare Data Linkage". The conference was full of enlightening speeches that reflected the progress made in the field of medical informatics. With a total of 1,039 participants, this conference was held on the largest scale ever among KOSMI conferences. 

The book 'There's no such thing as K-Quarantine', written by Prof.Howard Lee, Jung-Hyun Won, YeSol Hong and 13 others, was selected in the liberal arts section of the Sejong Cultural Book Program this year. The Sejong Cultural Book Program is organized by the Publication industry Promotion Agency of Korea. This program aims to promote domestic publishing activities and to build a knowledge-based society by selecting outstanding books among those published throughout the year. Books worth 8 million Korean won will be distributed to public libraries nationwide. In 2022, 550 books were selected from a total of 8,698 candidates. The book There's no such thing as K-quarantine was selected as an excellent book in the field of technology science. 

In the first quarter of 2021, CCADD got off to a good start with a new project deal with Korea Ginseng Corporation (KGC).

Korea’s leading ginseng brand for over a century, KGC has a distinguished track record of making quality dietary products. CCADD, on the other side of the deal, has been receiving high marks on its clinical science expertise. So, the handshake between the two definitely holds the promise of achieving something big and previously unimagined.

And the promise is becoming real. Staring this March, KGC and CCADD set out on a project to develop a mobile healthcare application called ‘Care Now Q.’ Once complete, the mobile application will be the first in the market that utilizes data from medical checkups, direct-to-consumer genetic tests, and health survey results to recommend individualized health guidance and dietary supplement suggestions. For this ambitious project, CCADD will play an active role as a clinical expert and project manager, providing expertise and orchestrating the entire process. This project will be led by Yoomin Jeon (team leader), Jung-Hyun Won, and David Seung U Lee under the supervision of Prof. Howard Lee.

The stakes are high. This project will not only turn the idea of individualized health management into reality but also open the door for CCADD to a new area of research, moving forward.